Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prednisolone Hemisuccinate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 8/20 | 0.76 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.94 |
| ▸ | LMNA | P02545 | 2/20 | 0.94 |
| ▸ | PGR | P06401 | 4/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.76 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.76 |
| ▸ | TNF | P01375 | 2/20 | 0.76 |
| ▸ | IL6 | P05231 | 1/20 | 0.76 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.76 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.76 |
| ▸ | AR | P10275 | 1/20 | 0.76 |
| ▸ | GLUL | P15104 | 1/20 | 0.76 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.76 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.76 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prednisolone Hemisuccinate SCHEMBL871872 | 0.97 | HIF1A (1.00) | HIF1ALMNANR3C1PGRCYP3A4 | |
| Prednisolone Hemisuccinate SCHEMBL122046 | 0.97 | HIF1A (1.00) | HIF1ALMNANR3C1PGRCYP3A4 | |
| Prednisolone SCHEMBL122047 | 0.93 | NR3C1 (0.88) | HIF1ALMNANR3C1PGRCYP3A4 | |
| Prednisolone SCHEMBL2234173 | 0.93 | NR3C1 (0.88) | HIF1ALMNANR3C1PGRCYP3A4 | |
| Prednisolone SCHEMBL8432080 | 0.92 | HIF1A (0.80) | HIF1ALMNANR3C1PGRCYP3A4 | |
| Prednisolone SCHEMBL8718052 | 0.92 | HIF1A (0.80) | HIF1ALMNANR3C1PGRCYP3A4 | |
| Prednisolone SCHEMBL704873 | 0.92 | HIF1A (0.80) | HIF1ALMNANR3C1PGRCYP3A4 | |
| SCHEMBL16009510 | 0.92 | HIF1A (0.91) | HIF1ALMNANR3C1PGRCYP3A4 | |
| Prednisolone SCHEMBL7999833 | 0.90 | NR3C1 (0.82) | HIF1ALMNANR3C1PGRCYP3A4 | |
| Prednisolone Hemisuccinate SCHEMBL25138782 | 0.89 | HIF1A (0.85) | HIF1ALMNANR3C1PGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150005265-A1 | METHODS AND COMPOSITIONS FOR COMBINATION THERAPY USING P13K/MTOR INHIBITORES | TOKAI PHARMACEUTICALS, INC. | 2015-01-01 | — | — | US | disclosed |
| EP-2793896-A1 | METHODS AND COMPOSITIONS FOR COMBINATION THERAPY USING P13K/MTOR INHIBITORS | Tokai Pharmaceuticals, Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013096907-A1 | METHODS AND COMPOSITIONS FOR COMBINATION THERAPY USING P13K/MTOR INHIBITORS | TOKAI PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20110319369-A1 | COMBINATION OF A 17 ALPHA-HYDROXYLASE/C17, 20-LYASE INHIBITOR WITH AN ADDITIONAL THERAPEUTIC AGENT | TOKAI PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2010091299-A2 | NOVEL COMBINATION CANCER THERAPIES | TOKAI PHARMACEUTICALS (US) | 2010-08-12 | — | — | WO | disclosed |
| US-7173129-B2 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | ATHERO GENICS, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20050049236-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | CRABTREE ACQUISITION CO, LLC | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319369-A1 | COMBINATION OF A 17 ALPHA-HYDROXYLASE/C17, 20-LYASE INHIBITOR WITH AN ADDITIONAL THERAPEUTIC AGENT | CYP17A1, CYP21A2, HSD17B1 | NR3C1 475/4885HIF1A 742/4885LMNA 3599/4885 |
| US-20050049236-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | STS, HPSE, SULT1E1 | NR3C1 410/4885HIF1A 1182/4885LMNA 2762/4885 |
| US-20150005265-A1 | METHODS AND COMPOSITIONS FOR COMBINATION THERAPY USING P13K/MTOR INHIBITORES | MTOR, CYP17A1, CYP19A1 | NR3C1 686/4885HIF1A 1102/4885LMNA 2740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.